title: Comparison of prognostic value of in vitro drug resistance and bone marrow residual disease on day 15 of therapy in childhood acute lymphoblastic leukemia.
abstract: OBJECTIVE
  The analysis of the prognostic impact of residual disease at day 15 of induction therapy, individual tumor response testing (ITRT) at diagnosis, initial factors and initial therapy response to the risk of relapse in children with precursor B-cell acute lymphoblastic leukemia (ALL).
  
  
  METHODS
  A total of 87 children were tested at diagnosis for ITRT and for persistence of blasts in bone marrow at day 15 (BML15>0.5%) and were followed-up in long-term analysis.
  
  
  RESULTS
  The probability of disease-free survival (pDFS) was significantly better for patients with an ITRT profile showing sensitivity to prednisolone, vincristine, daunorubicin, and L-asparaginase. Patients with BML15>0.5% had higher ITRT for prednisolone, daunorubicin, L-asparaginase, and etoposide. Three factors had predictive impact for relapse: BML15>0.5%, ITRT for prednisolone and high combined ITRT profile for prednisolone, vincristine and L-asparaginase (PVA score).
  
  
  CONCLUSIONS
  Persistence of blasts in bone marrow at day 15, ITRT showing resistance to prednisolone and high PVA score were the strongest and comparable prognostic factors predicting relapse in childhood ALL.
authors.affiliation: Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, ul. Curie-Sklodowskiej 9, 85-094 Bydgoszcz, Poland. jstyczynski@cm.umk.pl
authors.forename: Jan
authors.initials: J
authors.lastname: Styczynski
authors.forename: Magdalena
authors.initials: M
authors.lastname: Piatkowska
authors.forename: Anna
authors.initials: A
authors.lastname: Jaworska-Posadzy
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Czyzewski
authors.forename: Malgorzata
authors.initials: M
authors.lastname: Kubicka
authors.forename: Beata
authors.initials: B
authors.lastname: Kolodziej
authors.forename: Beata
authors.initials: B
authors.lastname: Kurylo-Rafinska
authors.forename: Robert
authors.initials: R
authors.lastname: Debski
authors.forename: Monika
authors.initials: M
authors.lastname: Pogorzala
authors.forename: Mariusz
authors.initials: M
authors.lastname: Wysocki
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001215:Asparaginase / Q000494:pharmacology; D001853:Bone Marrow / Q000473:pathology*; D002648:Child; D002675:Child, Preschool; D003630:Daunorubicin / Q000494:pharmacology; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D004354:Drug Screening Assays, Antitumor / Q000379:methods; D005047:Etoposide / Q000494:pharmacology; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D015999:Multivariate Analysis; D018365:Neoplasm, Residual; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood / Q000188:drug therapy* / Q000473:pathology*; D011239:Prednisolone / Q000494:pharmacology; D011379:Prognosis; D014750:Vincristine / Q000494:pharmacology
chemical_list: D000970:Antineoplastic Agents; D014750:Vincristine; D005047:Etoposide; D011239:Prednisolone; D001215:Asparaginase; D003630:Daunorubicin